Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: A novel mechanism for induction of apoptosis in CML cells

Leukemia

Volumn 27, Issue 7, 2013, Pages 1567-1570

  Wagner, M C ^a   Dziadosz, M ^a   Melo, J V ^b   Heidel, F ^a   Fischer, T ^a   Lipka, D B ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b An alliance between SA Pathology and the University of South Australia   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; STAT5 PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER PATIENT; CELL CULTURE; CHRONIC MYELOID LEUKEMIA; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; IC 50; IN VITRO STUDY; INTRACELLULAR MEMBRANE; LETTER; LEUKEMIA CELL; LEUKEMIA CELL LINE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

APOPTOSIS; CELL LINE, TUMOR; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; PULSE THERAPY, DRUG; PYRIMIDINES;

EID: 84880288155     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.364     Document Type: Letter

References (19)

1. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
2. Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005; 11: 6414-6421.
3. Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007; 13: 1367-1373.
4. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542-2551.
5. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531-2541.
6. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-819.
7. le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1999; 91: 163-168
8. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008; 111: 4022-4028.
9. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109: 3496-3499.
10. Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008; 14: 485-493.
11. Snead JL, O'Hare T, Adrian LT, Eide CA, Lange T, Druker BJ et al. Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood 2009; 114: 3459-3463.
12. Hiwase DK, White DL, Saunders VA, Kumar S, Melo JV, Hughes TP. Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells. Leukemia 2009; 23: 1205-1206.
13. Lipka DB, Wagner M-C, Dziadosz M, Schnöder T, Heidel F, Schemionek M et al. Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells. PLoS One 2012; 7: e40853.
14. Hegedu+s C,Özvegy-Laczka C, Apá tiÁ , Magó csi M, Német K, O+ rfi L et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 2009; 158: 1153-1164.
15. Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF et al. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Disposition 2010; 38: 1371-1380.
16. Dziadosz M, Wagner M-C, Lipka DB, Fischer T, Bartels H. High-performance liquid chromatography with ultraviolet detection and protein precipitation as a way of quantitative determination of nilotinib with and without internal standard. J Liq Chromatogr Relat Techno 2012.
17. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141.
18. Manley PW, Cowan-Jacob S, Fendrich G, Liebetanz J, Mestan J, Martin N, Fabbro D. 100th Annual Meeting of the American Association for Cancer Research; 18-22 April, 2009; Abstract no. 3715.
19. Manley PW, Cowan-Jacob SW, Fendrich G, Jahnke W, Fabbro D. Nilotinib, in comparison to both dasatinib and imatinib, possesses a greatly prolonged residence time when bound to the BCR-ABL kinase SH1 domain. Blood (ASH Annu Meet Abstr) 2011; 118: 1674.